The activity of BP/LPPC, BP or BP + LPPC was estimated by measuring the cytotoxicity toward cancer cells. 3.4. in LPPC. In HT-29 and CT26 H4 Receptor antagonist 1 cells, BP/LPPC showed greater cytotoxicity (IC50 = 11.06 0.37C27.60 1.10 g/mL, 24 h) than BP (IC50 = 145.32 0.35C213.41 2.04 g/mL, 24 h) and BP + LPPC (IC50 = 121.6 6.64C176.81 4.56 g/mL, 24 h) after storage at H4 Receptor antagonist 1 4 C in H2O (Figure 1b,c). In addition, BP/LPPC (IC50 = 14.57 0.15C38.38 5.91 g/mL, 24 h) also displayed greater cytotoxicity than the BP group (IC50 = 138.03 2.88C173.25 0.52 g/mL, 24 h) and BP + LPPC (IC50 = 155.02 2.96C188.14 0.3 g/mL, 24 h) after storage at 37 C in PBS containing 10% FBS (Determine 1d,e). The IC50 value was rapidly increased in the BP group and BP + LPPC group after an incubation at 4 C or 37 C for 4C24 h, but was not obviously altered in the BP/LPPC groups. The structure of BP was reported to be very easily hydrated or oxidized, and thus, the biological functions of BP may be altered or the activity lost after dissolution in an aqueous answer. However, the BP activity was managed or increased in the BP/LPPC group, suggesting that LPPC encapsulation stabilized the BP structure and improved its antitumor activity. 2.3. LPPC Encapsulation Increased Cell Uptake of BP through Induction of Clathrin-Mediated Endocytosis Previous studies of liposomes revealed that liposomes decrease drug penetration into normal organs, maintain drug stability and increase cellular uptake [19,20,21,22,23]. Next, we quantitatively and qualitatively investigated whether LPPC encapsulation promotes the uptake of BP in CRC cells. After drug treatment, the BP fluorescence was observed in cells in the BP/LPPC group at 15 min and in the BP group at 60 min (Physique 2a). The BP values of cell uptake in the BP/LPPC group (12.78 0.22C20.37 1.21 g/2.5 105 cells) were greater than in the BP group (1.42 0.01C7.97 2.17 g/2.5 105 cells) from 15 to 60 min after treatment (Determine 2b), indicating that LPPC encapsulation increased the rate of BP uptake in CRC cells. Open in a separate window Physique 2 LPPC encapsulation promoted the cellular uptake of BP via the clathrin-mediated endocytosis pathway. (a) HT-29 cells were treated with BP/LPPC (50 g/mL) or BP (50 g/mL) for 0, 15, 30, 45 or 60 min and the cellular uptake of BP (blue fluorescence) was observed using an upright fluorescence microscope. (b) HT-29 cells were incubated with BP/LPPC (50 g/mL) or BP (50 g/mL), BP was extracted with phenol-chloroform, and BP levels in cells were determined using a fluorescence spectrophotometer to quantify cellular uptake. * 0.05 compared with the BP group. (c) HT-29 cells were pretreated with the endocytosis inhibitors AHH (13.31 g/mL), FIII (1 g/mL) and CPZ (10 g/mL) for 1 h; then, cells were treated with BP/LPPC (50 g/mL) and the BP levels in cells were determined as explained above. # 0.05 compared with the control. Liposomes with a positive charge trigger endocytosis to increase cellular Rabbit Polyclonal to TPIP1 uptake [40,41]. In our previous study, the average zeta potential of BP/LPPC was ~38 mV [37], which may induce cell endocytosis. Cells were pretreated with the H4 Receptor antagonist 1 endocytosis inhibitors AHH (micropinocytosis), FIII (caveolae-mediated endocytosis) or CPZ (clathrin-mediated endocytosis) prior to the BP/LPPC treatment to determine which endocytosis pathway was involved in BP/LPPC uptake. The cells were collected, and the BP levels were measured; all inhibitors reduced the cellular uptake of BP compared with the control group (12.78 0.22C19.71 0.24 g/2.5 105 cells) from 15 to 90 min, particularly in the CPZ groups (1.86 0.03C3.30 0.02 g/2.5 105 cells; Physique 2c). LPPC encapsulation brought on cellular endocytosis to increase the uptake of BP into CRC cells through the clathrin-mediated endocytosis pathway. However, the phenomenon H4 Receptor antagonist 1 was not observed H4 Receptor antagonist 1 in normal cells (data not shown), potentially due to the differences in the characteristics of normal and malignancy cells. Furthermore, this house of LPPC may be useful for distinguishing normal and malignancy cells to reduce drug-related side effects during therapy. 2.4. BP/LPPC Induce Cell Cycle Arrest and Cell Apoptosis in Colorectal Malignancy Cells Cells were treated with.